About: SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine
Creator	Belka, Claus Corradini, Stefanie Niyazi, Maximilian Grabein, Béatrice Keppler, Oliver Boelke, Edwin Marschner, Sebastian Mayerle, Julia Petru, Raluca Rauch, Josefine Sujic, Ana Zacharias, Richard
Source	Medline; PMC
abstract	BACKGROUND: Starting in December 2019, the current pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confronts the world with an unprecedented challenge. With no vaccine or drug being currently available to control the pandemic spread, prevention and PCR (Polymerase chain reaction) testing becomes a crucial pillar of medical systems. Aim of the present study was to report on the first results of the measures taken in a large German Department of Radiation Oncology, including PCR testing of asymptomatic cancer patients. METHODS: Pandemic-adapted hygiene regulations and prevention measures for patients and staff were implemented. A visiting ban on both wards was implemented from the beginning and medical staff and patients were required to wear face masks at all times. The waiting rooms were rearranged to ensure distance between patients of at least 1.5 m. Clinical follow up was mainly done by telephone and all patients had to complete a questionnaire regarding symptoms and contacts with COVID-19 patients before entering our department. Educational documents were created for patients to raise awareness of symptoms and avoidance strategies for interactions with other people. Indications for therapy and fractionation schemes were adapted when possible. In a subsequent step, all new asymptomatic patients were tested via nasopharyngeal swab at our screening station shortly before their simulation CT. RESULTS: All these measures and implementations have been well accepted semiquantitatively measured by the consent received from patients and staff. Regarding the PCR testing, only 1 out of 139 asymptomatic patients of our cohort so far tested positive for SARS-CoV-2, reflecting a prevalence of 0.72% in this cancer patient population. Up to this point no staff members was tested positive. The start of the treatment for the PCR-positive patient was deferred for 2 weeks. CONCLUSION: Due to the pandemic-adapted implementations, our department seems well prepared during this crisis. The initial screening helps to identify asymptomatic COVID-19 patients in order to protect other patients and our staff from infection and the observed PCR prevalence is in line with comparable studies. A regular PCR testing (e.g. twice a week) of all patients and staff would in principle be desirable but is limited due to testing capacities at present.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1186/s13014-020-01609-0
bibo:pmid	32646505
has license	cc-by
sha1sum (hex)	715126f5663f4414630390a5250c21791dde97e7
schema:url	https://doi.org/10.1186/s13014-020-01609-0
resource representing a document's title	SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine
has PubMed Central identifier	PMC7344028
has PubMed identifier	32646505
schema:publication	Radiat Oncol
resource representing a document's body	covid:715126f5663f4414630390a5250c21791dde97e7#body_text
is schema:about of	named entity 'control' named entity 'times' named entity 'testing' named entity 'therapy' named entity 'measures' named entity 'prevention' named entity 'INTERACTIONS' named entity 'TELEPHONE' named entity 'NASOPHARYNGEAL SWAB' named entity 'RADIATION ONCOLOGY' named entity 'CAUSED BY' named entity 'raise' named entity 'questionnaire' named entity 'ensure' named entity 'pandemic' named entity 'visiting' named entity 'distance' named entity 'entering' named entity 'measures' named entity 'asymptomatic' named entity 'SARS-CoV-2' named entity 'asymptomatic patients' named entity 'PCR' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'hygiene' named entity 'asymptomatic' named entity 'Robert Koch Institute' named entity 'Radiotherapy' named entity 'RNA' named entity 'test kits' named entity 'diagnostic imaging' named entity 'April 2020' named entity 'SARS' named entity 'vascular inflammation' named entity 'virus' named entity 'infection' named entity 'SARS-CoV-2' named entity 'radiotherapy' named entity 'FFP2' named entity 'Good Clinical Practice' named entity 'infection' named entity 'asymptomatic' named entity '1, 2' named entity 'PCR' named entity 'immunosuppression' named entity 'social distancing' named entity 'extrapulmonary' named entity 'oncology' named entity 'inflammatory' named entity 'radiation oncology' named entity 'measles' named entity 'Radiation oncology' named entity 'WHO' named entity 'asymptomatic patients' named entity 'radiotherapy' named entity 'SARS-CoV-2' named entity 'preventive measures' named entity 'comorbidities' named entity 'lungs' named entity 'public health care' named entity 'radiotherapy' named entity 'test kits' named entity 'tumor' named entity 'infection' named entity 'medical staff' named entity 'droplet' named entity 'Wuhan' named entity 'RTTs' named entity 'outpatient' named entity 'heart disease'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software